BridgeBio Publishes Presentation on Encaleret Phase 3 CALIBRATE Results

• BridgeBio Pharma published a medical research presentation detailing 24-week results from the phase 3 CALIBRATE trial of encaleret in autosomal dominant hypocalcemia type 1.
• The composite serum and urinary calcium endpoint was achieved by 76% of encaleret recipients versus 19% receiving standard care (p<0.0001).
• Mean eGFR increased by 11 mL/min/1.73 m² with encaleret versus 3 mL/min/1.73 m² with standard care.
• Serious treatment-emergent adverse events occurred in 9% of encaleret recipients versus 14% receiving standard care.
• No treatment-emergent adverse events led to encaleret discontinuation during randomized treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief on October 24, 2026, and is solely responsible for the information contained therein.